2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4064人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995572, encodeId=398d19955e250, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, objectType=article, longId=179046, objectId=34e61e9046bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e61e9046bc, replyNumber=0, likeNumber=80, createdTime=2019-11-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e61e9046bc, moduleTitle=Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e61e9046bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995550, encodeId=84071995550bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响, objectType=article, longId=159506, objectId=5b8515950618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b8515950618, replyNumber=0, likeNumber=103, createdTime=2019-03-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b8515950618, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b8515950618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995558, encodeId=0243199555852, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, objectType=article, longId=164498, objectId=282016449820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282016449820, replyNumber=0, likeNumber=0, createdTime=2020-01-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282016449820, moduleTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282016449820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995548, encodeId=12c1199554824, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, objectType=article, longId=158906, objectId=356b158906ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356b158906ea, replyNumber=0, likeNumber=51, createdTime=2019-11-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356b158906ea, moduleTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356b158906ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995559, encodeId=5f3b199555981, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：钠-葡萄糖共转运体2抑制剂可降低24小时血压, objectType=article, longId=165387, objectId=fa9d16538e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9d16538e5b, replyNumber=0, likeNumber=94, createdTime=2019-07-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9d16538e5b, moduleTitle=Circulation：钠-葡萄糖共转运体2抑制剂可降低24小时血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9d16538e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995547, encodeId=2283199554e67, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=J Diabetes Res：钠 - 葡萄糖协同转运蛋白2抑制剂对糖尿病视网膜病变的治疗效果研究, objectType=article, longId=158467, objectId=639d15846ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=639d15846ebc, replyNumber=0, likeNumber=118, createdTime=2019-08-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=639d15846ebc, moduleTitle=J Diabetes Res：钠 - 葡萄糖协同转运蛋白2抑制剂对糖尿病视网膜病变的治疗效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=639d15846ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995562, encodeId=81cb199556278, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, objectType=article, longId=173295, objectId=7d9e1e32952a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9e1e32952a, replyNumber=0, likeNumber=86, createdTime=2019-10-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9e1e32952a, moduleTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d9e1e32952a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995553, encodeId=978819955538d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, objectType=article, longId=161781, objectId=2f85161e81f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f85161e81f8, replyNumber=0, likeNumber=68, createdTime=2019-12-06, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f85161e81f8, moduleTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f85161e81f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995537, encodeId=b04e199553eca, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析, objectType=article, longId=148897, objectId=5a5a14889e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5a14889e0f, replyNumber=0, likeNumber=143, createdTime=2019-03-02, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5a14889e0f, moduleTitle=Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a5a14889e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995541, encodeId=6438199554106, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=NEJM：选择性酪氨酸激酶2抑制剂用于银屑病的2期试验, objectType=article, longId=150368, objectId=0adb150368c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0adb150368c5, replyNumber=0, likeNumber=0, createdTime=2019-05-25, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0adb150368c5, moduleTitle=NEJM：选择性酪氨酸激酶2抑制剂用于银屑病的2期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0adb150368c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995543, encodeId=436b1995543c7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, objectType=article, longId=152526, objectId=ad2715252671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad2715252671, replyNumber=0, likeNumber=68, createdTime=2019-07-24, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad2715252671, moduleTitle=Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad2715252671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995532, encodeId=9ea0199553232, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？, objectType=article, longId=144604, objectId=dfa914460422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa914460422, replyNumber=0, likeNumber=77, createdTime=2019-01-08, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa914460422, moduleTitle=JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa914460422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995554, encodeId=d2b81995554db, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险, objectType=article, longId=161782, objectId=aad0161e82c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aad0161e82c0, replyNumber=0, likeNumber=106, createdTime=2019-05-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad0161e82c0, moduleTitle=JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad0161e82c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995549, encodeId=af6d199554985, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？, objectType=article, longId=159182, objectId=207b1591827c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207b1591827c, replyNumber=0, likeNumber=63, createdTime=2019-04-05, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207b1591827c, moduleTitle=观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=207b1591827c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995526, encodeId=2f501995526a3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类, objectType=article, longId=139721, objectId=9b09139e213c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b09139e213c, replyNumber=0, likeNumber=68, createdTime=2019-04-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b09139e213c, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b09139e213c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995552, encodeId=1e2919955523d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JACC Heart Failure：钠-葡萄糖协同转运蛋白2抑制剂用于心血管疾病的全新实用指导, objectType=article, longId=160801, objectId=f61f1608016b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f61f1608016b, replyNumber=0, likeNumber=63, createdTime=2019-07-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f61f1608016b, moduleTitle=JACC Heart Failure：钠-葡萄糖协同转运蛋白2抑制剂用于心血管疾病的全新实用指导, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f61f1608016b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995538, encodeId=0bca1995538a3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？, objectType=article, longId=149241, objectId=d458149241bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d458149241bb, replyNumber=0, likeNumber=101, createdTime=2019-04-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d458149241bb, moduleTitle=JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d458149241bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995540, encodeId=53e91995540d3, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=61, createdTime=2019-01-15, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995542, encodeId=8082199554213, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JACC：可溶性肿瘤因子2抑制剂可预测慢性心衰预后, objectType=article, longId=152467, objectId=45d715246ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d715246ea1, replyNumber=0, likeNumber=0, createdTime=2019-07-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d715246ea1, moduleTitle=JACC：可溶性肿瘤因子2抑制剂可预测慢性心衰预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d715246ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995545, encodeId=41a819955456b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMJ：钠葡萄糖协同转运蛋白2抑制剂和严重不良事件的风险, objectType=article, longId=153570, objectId=f6661535e07d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6661535e07d, replyNumber=0, likeNumber=70, createdTime=2018-12-02, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6661535e07d, moduleTitle=BMJ：钠葡萄糖协同转运蛋白2抑制剂和严重不良事件的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6661535e07d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet Diabetes Endo：SGLT2抑制剂的肾脏保护作用

2019-11-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT2抑制剂对2型糖尿病和慢性肾病患者的心血管、肾脏和安全性结局的影响

2019-03-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%

2020-01-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病

2019-11-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：钠-葡萄糖共转运体2抑制剂可降低24小时血压

2019-07-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

J Diabetes Res：钠 - 葡萄糖协同转运蛋白2抑制剂对糖尿病视网膜病变的治疗效果研究

2019-08-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究

2019-10-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化

2019-12-06

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：与SGLT2抑制剂相关的生殖器感染风险分析

2019-03-02

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

NEJM：选择性酪氨酸激酶2抑制剂用于银屑病的2期试验

2019-05-25

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetic Med：钠-葡萄糖共转运蛋白-2抑制剂依帕列净在2型糖尿病年轻人中的药代动力学和药效学特征

2019-07-24

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JACC：SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险？

2019-01-08

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JCEM：SGLT2抑制剂增加了糖尿病酮症酸中毒的风险

2019-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

观察性研究中使用SGLT2抑制剂死亡风险较低：真实还是偏倚？

2019-04-05

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类

2019-04-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JACC Heart Failure：钠-葡萄糖协同转运蛋白2抑制剂用于心血管疾病的全新实用指导

2019-07-14

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA Intern Med：SGLT-2抑制剂增加2型糖尿病患者截肢风险？

2019-04-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2019-01-15

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JACC：可溶性肿瘤因子2抑制剂可预测慢性心衰预后

2019-07-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMJ：钠葡萄糖协同转运蛋白2抑制剂和严重不良事件的风险

2018-12-02

科室
- - 订阅+
  - 更多科室
工具
服务